Zydus Lifesciences US arm wins USFDA nod for Levothyroxine Sodium for Injection to treat myxedema coma
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.;
Ahmedabad: Zydus Lifesciences Limited's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial. Levothyroxine Sodium injection manufactured by Fresenius Kabi USA, LLC.
Myxedema coma is an extreme or decompensated form of hypothyroidism and, while uncommon, is potentially lethal. Primary symptoms of the disease are low body temperature and altered mental status.
Levothyroxine Sodium injection is indicated for the treatment of myxedema coma.
Read also: Zydus Naftifine HCL 2% Cream Gets CDSCO Panel nod to treat superficial fungal infection of skin
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.